Phase 2 N=38 Treatment

The Role of Endothelin in Pulmonary Hypertension

Pulmonary Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT00759408 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2018

Primary outcome: Primary: Pulmonary Vascular Resistance (PVR) — 64; 119; 67; 46 dyn*sec/cm^5

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: BQ-123 (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Brigham and Women's Hospital
Primary completion: Oct 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Pulmonary Vascular Resistance (PVR)	64; 119; 67; 46; 85	—
SECONDARY Systemic Vascular Resistance (SVR)	1368; 1050; 1351; 1069; 828	—
SECONDARY Mean Pulmonary Artery Pressure (PAP)	10; 15; 10; 9; 14	—
SECONDARY Cardiac Output (CO)	5.3; 6.7; 5.2; 6.4; 8.3	—

Summary

The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.

Eligibility Criteria

Inclusion Criteria

Healthy volunteers or known diagnosis of pulmonary hypertension

Exclusion Criteria

hypertension due to other reasons (not pulmonary)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00759408). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.